Shares of Compass Pathways PLC Sponsored ADR (NASDAQ:CMPS - Get Free Report) traded up 5% on Thursday. The company traded as high as $8.45 and last traded at $8.5220. 1,533,113 shares traded hands during trading, a decline of 56% from the average daily volume of 3,482,406 shares. The stock had previously closed at $8.12.
Analyst Ratings Changes
CMPS has been the subject of several research reports. HC Wainwright reiterated a "buy" rating on shares of Compass Pathways in a research report on Monday, November 9th. Wells Fargo & Company lowered their price objective on Compass Pathways from $13.00 to $10.00 and set an "equal weight" rating for the company in a research note on Wednesday, November 4th. Wall Street Zen raised Compass Pathways from a "sell" rating to a "hold" rating in a research note on Monday. Jefferies Financial Group restated a "buy" rating on shares of Compass Pathways in a report on Monday, November 9th. Finally, BTIG Research reaffirmed a "buy" rating and set a $25.00 price target on shares of Compass Pathways in a research report on Tuesday, November 3rd. One equities research analyst has rated the stock with a Strong Buy rating, fourteen have issued a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and an average target price of $23.14.
Read Our Latest Analysis on CMPS
Compass Pathways Stock Performance
The company has a market capitalization of $1.22 billion, a price-to-earnings ratio of -2.48 and a beta of 2.43. The company has a 50 day moving average price of $11.53 and a 200 day moving average price of $10.48. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.50 and a current ratio of 1.50.
Compass Pathways (NASDAQ:CMPS - Get Free Report) last issued its earnings results on Tuesday, November 3rd. The company reported ($0.31) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.39) by $0.08. Equities research analysts predict that Compass Pathways PLC Sponsored ADR will post -0.78 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Compass Pathways
Several institutional investors have recently bought and sold shares of CMPS. Orbimed Advisors LLC purchased a new position in shares of Compass Pathways in the 1st quarter worth approximately $6,363,000. Affinity Asset Advisors LLC boosted its position in Compass Pathways by 454.2% in the first quarter. Affinity Asset Advisors LLC now owns 1,108,483 shares of the company's stock worth $6,130,000 after purchasing an additional 908,483 shares during the last quarter. Eversept Partners LP bought a new position in Compass Pathways in the 1st quarter valued at $3,749,000. Creek Drive Management Group LLC grew its stake in Compass Pathways by 91.9% in the 3rd quarter. Creek Drive Management Group LLC now owns 1,328,000 shares of the company's stock valued at $16,520,000 after purchasing an additional 636,000 shares during the period. Finally, CenterBook Partners LP boosted its holdings in shares of Compass Pathways by 454.1% in the 3rd quarter. CenterBook Partners LP now owns 695,943 shares of the company's stock worth $8,658,000 after buying an additional 570,349 shares during the last quarter. Institutional investors own 46.19% of the company's stock.
About Compass Pathways
(
Get Free Report)
Compass Pathways plc is a biotechnology company developing treatments for mental health conditions. Founded in 2016 by George Goldsmith and Ekaterina Malievskaia, the company is focused on advancing psychedelic-based therapies through clinical research. Its lead investigational product, COMP360, is a synthetic formulation of psilocybin being studied alongside psychological support. Compass is evaluating COMP360 primarily as a potential treatment for treatment-resistant depression and has also explored its use for other mental health conditions, including post-traumatic stress disorder.
Read More
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Compass Pathways, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Compass Pathways wasn't on the list.
While Compass Pathways currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
The AI boom is creating opportunities across semiconductors, cloud computing, enterprise software, infrastructure, cybersecurity, and automation.
Inside this report, you’ll find 10 companies positioned to benefit as artificial intelligence moves from hype to real-world deployment and becomes a core growth driver for corporate America.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.